ImmunityBio (IBRX) said Monday it has asked for a prompt meeting with the US Food and Drug Administration after the agency declined to review its supplemental application for ANKTIVA in combination with Bacillus Calmette-Guerin, or BCG, to treat bladder cancer that is unresponsive to BCG and has not spread to surrounding tissue.
The company said the FDA's refusal contradicted earlier direction given during a January meeting where senior officials reportedly supported the filing of the application based on a single trial's results from QUILT 3.032.
The previously approved use of ANKTIVA in patients with both papillary tumors and CIS had been based on the same clinical study, the company said, highlighting what it sees as a conflicting regulatory stance.
ImmunityBio cited long-term results in the papillary-only group, including over 96% survival specific to the disease at three years and more than 82% of patients avoiding bladder removal.
Shares of the company were down more than 8% in recent Monday premarket activity.
Price: 2.33, Change: -0.21, Percent Change: -8.27
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。